ReShape Short Term Debt from 2010 to 2024
| RSLS Stock | USD 0.25 0.03 10.71% |
Short Term Debt | First Reported 2005-12-31 | Previous Quarter 110 K | Current Value 111 K | Quarterly Volatility 3 M |
Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape main balance sheet or income statement drivers, such as Interest Expense of 24.7 K, Other Operating Expenses of 26.5 M or Total Operating Expenses of 24.6 M, as well as many exotic indicators such as Price To Sales Ratio of 0.16, Dividend Yield of 0.0 or PTB Ratio of 0.21. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.
ReShape | Short Term Debt |
Latest ReShape Lifesciences' Short Term Debt Growth Pattern
Below is the plot of the Short Term Debt of ReShape Lifesciences over the last few years. It is ReShape Lifesciences' Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ReShape Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| Short Term Debt | 10 Years Trend |
|
Short Term Debt |
| Timeline |
ReShape Short Term Debt Regression Statistics
| Arithmetic Mean | 1,977,711 | |
| Geometric Mean | 898,972 | |
| Coefficient Of Variation | 127.99 | |
| Mean Deviation | 1,643,281 | |
| Median | 1,267,000 | |
| Standard Deviation | 2,531,192 | |
| Sample Variance | 6.4T | |
| Range | 9.8M | |
| R-Value | (0.32) | |
| Mean Square Error | 6.2T | |
| R-Squared | 0.10 | |
| Significance | 0.25 | |
| Slope | (180,072) | |
| Total Sum of Squares | 89.7T |
ReShape Short Term Debt History
About ReShape Lifesciences Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ReShape Lifesciences income statement, its balance sheet, and the statement of cash flows. ReShape Lifesciences investors use historical funamental indicators, such as ReShape Lifesciences's Short Term Debt, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may use each financial statement separately, they are all related. The changes in ReShape Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ReShape Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ReShape Lifesciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ReShape Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Short Term Debt | 111 K | 105.5 K |
Pair Trading with ReShape Lifesciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ReShape Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ReShape Lifesciences will appreciate offsetting losses from the drop in the long position's value.Moving against ReShape Stock
| 0.53 | WST | West Pharmaceutical | PairCorr |
| 0.44 | SSY | SunLink Health Systems | PairCorr |
| 0.43 | FNA | Paragon 28 | PairCorr |
| 0.41 | CAH | Cardinal Health Fiscal Year End 20th of August 2024 | PairCorr |
The ability to find closely correlated positions to ReShape Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ReShape Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ReShape Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ReShape Lifesciences to buy it.
The correlation of ReShape Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ReShape Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ReShape Lifesciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ReShape Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of ReShape Lifesciences Correlation against competitors. For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for ReShape Stock analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is ReShape Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ReShape Lifesciences. If investors know ReShape will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ReShape Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 0.732 | Quarterly Revenue Growth (0.15) | Return On Assets (0.57) | Return On Equity (1.78) |
The market value of ReShape Lifesciences is measured differently than its book value, which is the value of ReShape that is recorded on the company's balance sheet. Investors also form their own opinion of ReShape Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is ReShape Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ReShape Lifesciences' market value can be influenced by many factors that don't directly affect ReShape Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ReShape Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ReShape Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ReShape Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.